Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of CHOP[cyclophosphamide + vincristine + doxorubicin + prednisone]/Rituxan Plus VELCADE [bortezomib] in Mediastinal Large B-Cell Lymphoma.

Next Previous
X
Search
Trial Profile

Phase II Study of CHOP[cyclophosphamide + vincristine + doxorubicin + prednisone]/Rituxan Plus VELCADE [bortezomib] in Mediastinal Large B-Cell Lymphoma.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Oct 2009 Actual number of patients (3) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 06 Jun 2008 Status changed from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top